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BACKGROUND: Notch receptor has an important role in both development and cancer. We previously reported that inhibition of the
Notch3 by g-secretase inhibitor (GSI) induces apoptosis and suppresses tumour proliferation in non-small-cell lung cancer. Although
radiation is reported to induce Notch activation, little is known about the relationship between radiation and Notch pathway.
METHODS: We examined the effect of combining GSI and radiation at different dosing in three Notch expressing lung cancer cell lines.
The cytotoxic effect of GSI and radiation was evaluated using MTT assay and clonogenic assay in vitro and xenograft models.
Expressions of Notch pathway, mitogen-activated protein kinase (MAPK) pathway and Bcl-2 family proteins were investigated using
western blot analysis.
RESULTS: We discovered that the antitumour effect of combining GSI and radiation was dependent on treatment schedule. g-Secretase
inhibitor administration after radiation had the greatest growth inhibition of lung cancer in vitro and in vivo. We showed that the combination
induced apoptosis of lung cancer cell lines through the regulation of MAPK and Bcl-2 family proteins. Furthermore, activation of Notch after
radiation was ameliorated by GSI administration, suggesting that treatment with GSI prevents Notch-induced radiation resistance.
CONCLUSION: Notch has an important role in lung cancer. Treatment with GSI after radiation can significantly enhance radiation-
mediated tumour cytotoxicity.
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Lung cancer is the most common cause of cancer related death in
the world, and the incidence is still increasing. Although several
therapies are available for advanced disease, they are palliative and
the cure rate remains very low for patients. New therapeutic
strategies are required to improve the poor prognosis of patients
with non-small-cell lung cancer (NSCLC).
Notch receptor is a single-pass transmembrane protein, which
regulates cell-fate determination in multi-cellular organisms. In
mammals, there are four Notch receptors (Noch1–Notch4) and two
families of ligands, Jagged (Jagged1 and -2) and Delta–like (Dll-1,
-3 and -4) (Allenspach et al, 2002; Iso et al, 2003). Upon ligand
binding, the Notch receptor undergoes a number of proteolytic
cleavages. The final cleavage by the g-secretase complex releases
the Notch intracellular domain (NICD), which forms a nuclear
complex with transcription factor CSL (CBF1, Sel, Lag-1) and
induces expression of target genes, such as the Hairy and enhancer
of split (HES) and Hairy/enhancer of split related with YRPW
(HEY) gene family (Weinmaster and Kopan, 2006).
Several studies have highlighted the aberrant activation of Notch
pathways in tumourigenesis of many cancers (Das et al, 2004; Curry
et al, 2005; Duechler et al, 2005; Reedijk et al,2 0 0 5 ) .W eh a v e
demonstrated that Notch3 is expressed in B40% of NSCLC tumours
and that suppression of Notch3 by dominant negative or g-secretase
inhibitor (GSI) inhibits growth of lung cancer both in vitro and
in vivo (Haruki et al, 2005; Konishi et al, 2007). g-Secretase inhibitor
modulates the Bcl-2 family proteins and downregulates MAPK
pathway (Konishi et al, 2007). Our group also reported that Bim,
BH3-only member of the Bcl-2 family proteins, is necessary for
Notch3-dependent apoptosis and that the effect of Notch3 on Bim is
through MAPK regulation (Konishi et al, 2010).
Although radiotherapy is routinely used to treat patients with lung
cancer, resistance to radiation is one of the major reasons for radio-
therapy failure in NSCLC. While many factors have been proven
contributing to this observation, radiation has been shown to activate
Notch in breast cancer and glioma. Given the role of Notch signalling
in oncogenesis, these observations suggest that Notch represents a
mechanism of radioresistance (Phillips et al, 2006; Wang et al, 2010).
In this study, we demonstrated the enhanced antitumour effect of
GSI after radiation in Notch expressing lung cancer cell lines in vitro
and in vivo. We also provide evidence that the observed antitumour
effect involves Notch pathway. The mechanism involves apoptosis
through the regulation of MAPK and Bcl-2 family proteins. Thus, our
findings will help define a new strategy in modulating radiation therapy
to enhance clinical efficacy in the treatment of patients with NSCLC.
MATERIALS AND METHODS
Cell lines and inhibitors
HCC2429 was established as previously described (Dang et al,
2000). The NSCLC cell lines, H460, A549 and H1395 were obtained
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sfrom American Type Culture Collection (Manassas, VA, USA).
Cell lines were maintained in RPMI supplemented with 10% foetal
calf serum at 371C in a humid environment in 5% CO2. g-Secretase
inhibitor I (in vitro) and GSI XX (in vitro, in vivo) were obtained
from Calbiochem (San Diego, CA, USA).
MTT proliferation assay
HCC2429 at 10000 cells per well, H460 and H1395 at 500 cells per
well were seeded into a 96-well plate and incubated overnight.
HCC2429 and H460 were shown previously to have high Notch3
expression, whereas H1395 did not express Notch (Konishi et al,
2007). The cells were treated with GSI I and radiation simulta-
neously, radiation at 24h after GSI I or GSI I at 24h post-radiation.
Treated cells were then incubated for 8 days. The MTT assay was
performed to according to manufacturer’s recommendation. The
absorption was determined at 560nm using the microplate reader
(Varioskan Flash; Thermo Fisher Scientific, Lafayette, CO, USA).
Clonogenic assay
HCC2429 at 5000 cells per well, H460 and H1395 at 2000 cells per
well were plated on 6-well plate and were then irradiated with 0 to
4Gy as indicated after an overnight incubation. g-Secretase inhibitor I
at varying doses was added at 24h after radiation and cells were
i n c u b a t e df o r8d a y s .T h ec e l l sw e r et h e nf i x e da n ds t a i n e df o r1m i n
with 0.5% crystal violet in methanol. The number of colonies was
counted manually. Survival fraction was calculated using the following
formula: mean colony counts/cells inoculated   plating efficiency
(PE). PE was defined as: mean colony counts/cells inoculated for
unirradiated controls, as previously described (Cao et al, 2004).
Quantification of interaction of combination
Combination index (CI) for the GSI and radiation was described
previously (Chou and Talalay, 1984; Gorodetsky et al, 1998).
Accordingly, CI was calculated as follows:
CI¼D/DxþC/Cxþ D/Dx C/Cx ðÞ : ð1Þ
Where Dx is the dose of radiation and Cx is the dose of GSI that
yields a selected level of survival (x) when each agent is used alone.
D is the dose of radiation and C is the dose of GSI that yields the
same survival (x) when both treatments were combined. The level
of survival selected to evaluate each set of combined treatments
is lower than the survival following radiation alone. Combination
index values are smaller than, equal to or greater than 1 represent
supra-additive, additive and sub-additive effects of the combined
treatment, respectively.
Apoptosis assays
HCC2429 and H460 were plated onto 6-well plates at the density of
1 10
6 cells per well and 3 10
5 cells per well respectively,
incubated overnight, and subsequently treated with GSI I 1mM for
HCC2429 and 9mM for H460 24h after 8Gy of radiation. HCC2429
and H460 were then incubated for 24 and 48h, respectively. The
cells were stained with FITC-conjugated Annexin V and propidium
iodide (PI), using Annexin V-FITC Apoptosis Detection kit and
according to manufacturer’s recommendation (Calbiochem). The
percentage of apoptotic cells was determined using a flow
cytometry (BD FACSCalibur; Becton, Dickinson and Company,
Franklin Lakes, NJ, USA).
Antibodies and western blot analysis
Notch3 was detected using a rabbit polyclonal antibody from Allele
Biotechnology and Pharmaceuticals, Inc. (San Diego, CA, USA) at
1:500. Notch1 was detected using a mouse monoclonal antibody
from Sigma-Aldrich Corp. (St Louis, MO, USA) at 1:500. The
rabbit antibodies to HES1 and HEY1 were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The rabbit
antibodies to Bcl-xL, phosphor-Bcl-2 (p-Bcl-2), Bcl-2, extracellular
signal-regulated kinase (ERK), p-ERK, AKT, p-AKT and poly
(ADP-ribose) polymerase (PARP) were obtained from Cell
Signaling Technology, Inc. (Danvers, MA, USA). Bim antibody
was obtained from Sigma-Aldrich Corp. The band intensity
was demonstrated by quantitative densitometric analysis using
NIH Image Ver1.62 software (NIH, Bethesda, MD, USA).
Standardisation was performed with actin measured in the same
blots with anti-actin antibody (A-2066, Sigma-Aldrich Corp.).
Quantifications were shown by the ratios of treated protein
expression/untreated protein expression.
In vivo tumourigenicity
All animal husbandry and experiments were performed under a
protocol approved by Institutional Animal Care Committee at
Hokkaido University School of Medicine. H460 and A549 at
1.0 10
6 cells were diluted in 100ml of PBS and injected
subcutaneously into right posterior legs of athymic, 5-week-old,
female nude mice (nuþ/nuþ). When the tumours were palpable,
the mice were randomly assigned to the radiation group, the GSI
group, the combination group or the control group. Each group
consisted of five mice. The mice in the radiation alone group
received 8Gy of radiation at day 1 and 8. The radiation was
administered to the tumour with the remainder of the body
shielded with lead. In the GSI group, 200mgkg
 1 GSI XX was
administered by i.p. at day 2, 3, 4 and 9, 10, 11, as previously
described (Tanaka et al, 2009; Konishi et al, 2010). The
combination group received both GSI XX and radiation in similar
schedule. The tumours were then measured every 2 days using a
digital caliper. Tumour volume (TV) was determined using the
formula: TV¼(Length) (Width) (Height)/2 (Cao et al, 2004).
Tumour growth rate (%TV) on day X was calculated as: (TV on
day X/TV on day1) 100, as previously described (Konishi et al,
2010). Some tumours were resected on day 15 and the expression
of NICD3 was determined by western blot analysis.
Statistical analysis
Determination of significance between the control and observation
arms of both in vitro and in vivo assays was analysed using the
non-parametric Mann–Whitney U test. Statistical significance was
established at the P valueo0.05. Calculations were performed
using SPSS, version 11.0.1 (SPSS Inc., Chicago, IL, USA).
RESULTS
Treatment with GSI at 24h after radiation enhanced
growth inhibition of lung cancer in vitro
To determine whether the combining GSI and radiation can inhibit
lung cancer proliferation, we treated Notch expressing lung cancer
cell lines, HCC2429 and H460 with increasing dose of GSI and
radiation. Cell viability of both cell lines was determined using the
MTT assay. Neither concurrent treatment schedule nor radiation
after GSI I administration had a significant impact on tumour
proliferation compared with single treatment with GSI I alone
(0Gy) (Figure 1A). In contrast, when GSI I was administrated after
radiation, there was a significant decrease in IC50 of GSI I
compared to treatment with GSI I alone (0Gy) in HCC2429 and
H460 (Figure 1B and Supplementary Table 1). Clonogenic assay
was performed to confirm the results of the MTT assay. This
treatment schedule resulted in greater suppression in colony
formations compared with radiation alone (Figure 1C). On the
other hand, in H1395, which does not express Notch, no difference
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sbetween single treatment and combination was observed in IC50
and colony formations (Figure 1B and C and Supplementary
Table 1), suggesting that combination is only effective in Notch
expressing cell lines. By determining the CI values of GSI I after
radiation in HCC2429 and H460, we noted supra-additive or
additive effects of combination in the most set of combining
treatment (Table 1). Therefore, this sequential treatment schedule
was employed in all of the following experiments.
GSI prevents radiation-dependent Notch activation
When HCC2429 and H460 were treated with GSI I alone, the expres-
sion of NICD in both cell lines was decreased in a dose-dependent
manner (Figure 2A). To investigate the effect of radiation on Notch
pathway, the expressions of NICD1, NICD3 and target genes, HES1
and HEY1 were assessed after cells were irradiated at 2 and 4Gy,
respectively. In HCC2429, the expression of NICD1 was upregulated
at 24h after radiation and this upregulation was observed up to
48h following radiation, whereas the expression of NICD3 was
unchanged. Notch1 mRNA was also upregulated after radiation,
suggesting that radiation induces transcripts of Notch1 (Supplemen-
tary Figure 1). In H460, in which the baseline expression of Notch3
level is lower, NICD3 expression was increased at 24 and 48h after
radiation and the expression of NICD1 was not induced by radiation
(Figure 2B). Notch3 mRNA was upregulated after radiation in H460
(Supplementary Figure 1). HEY1 expression was upregulated in both
cell lines at 48h after radiation compared with control. Then, we
examined NICD1 and NICD3 expression when cells were treated
with GSI I, radiation or the combination treatment. Radiation-
induced NICD1 upregulation was ameliorated by the combination
in HCC2429. Radiation-induced NICD3 enhancement was also
reduced by the combination in H460 (Figure 2C).
Addition of GSI enhances radiation-induced apoptosis
To examine whether addition of GSI following radiation can
induce apoptosis compared either treatment alone, we treated
HCC2429 and H460 with GSI I after radiation and determined the
proportion of apoptotic cells using Annexin V and PI and flow
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Figure 1 GSI after radiation suppressed proliferation of lung cancer. (A) Comparison of IC50 values in the different treatment schedule in the MTT
proliferation assay. Neither concurrent treatment schedule nor radiation after GSI I administration had a significant impact on tumour proliferation compared
with GSI I alone (0Gy). Plated cells were treated with GSI I and radiation simultaneously or radiation at 24h after GSI I administration (n¼5). Treated cells
were incubated for 8 days. GSI/R: concurrent treatment schedule. GSI-R: radiation after GSI I administration. (B) Comparison of IC50 in GSI I after
radiation. Plated cells were treated with GSI I at varying doses at 24h after radiation. IC50 was less for combined therapy than for GSI I alone in both
HCC2429 and H460 cell lines (n¼5). *Po0.05. On the contrary, IC50 was not different between GSI alone and combination in H1395. (C) GSI I after
radiation decreased clonogenic survival in HCC2429 and H460, but not in H1395 (n¼3). Cells were plated overnight and then exposed to radiation with 0
to 4Gy as indicated. GSI I at varying doses was added at 24h after radiation and then cells were incubated for 8 days.
Table 1 Combination index (CI) with respect to survival fraction of
HCC2429 and H460 cells exposed to GSI I after radiation
HCC2429 H460
Survival
fraction
(%)
Radiation
(D
a)( G y )
GSI
(C
a) lM CI
b
Survival
fraction
(%)
Radiation
(D
a)( G y )
GSI
(C
a) lM CI
b
50 2.0 0.47 0.96 50 2.0 1.29 0.93
50 3.0 0.28 1.00 50 3.0 0.98 1.00
50 4.0 0.20 1.10 50 4.0 0.68 1.21
25 2.0 0.56 0.78 25 2.0 1.64 0.83
25 3.0 0.45 0.86 25 3.0 1.56 0.99
25 4.0 0.31 0.87 25 4.0 1.46 1.10
10 2.0 0.66 0.66 10 2.0 2.43 0.84
10 3.0 0.65 0.76 10 3.0 2.26 0.91
10 4.0 0.64 0.86 10 4.0 1.98 0.94
Abbreviations: CI¼combination index; GSI¼g-secretase inhibitor.
aC and D were
obtained from the survival fraction curve (Figure 1C).
bCI was calculated for different
levels of survival fraction according to Equation 1.
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scytometry (Figure 3A). Either treatment induced apoptosis.
However, the combination increased apoptotic cells two or three
fold compared with either treatment alone (Figure 3B). When GSI
XX was used, we also noted the higher induction of apoptosis in
NSCLC cell lines (HCC2429, H460 and A549) with radiation
compared with either treatment alone (Supplementary Figure 2).
Combination alters p-ERK, anti-apoptotic proteins, and
pro-apoptotic proteins
As Notch has been shown to crosstalk with the epidermal growth
factor receptor pathway (Haruki et al, 2005), we assessed the
expression of phospo-ERK, a member of the MAPK family and
phospho-AKT. The combination reduced the expression of p-ERK
compared with either GSI I or radiation alone (Figure 4A).
Although several studies have shown the crosstalk between Notch
pathway and phosphatidylinositol 3-kinase (PI3K)/AKT pathway
(Wang et al, 2007; Meng et al, 2009), we observed no effect on
p-AKT level in any of the treatments (Figure 4A).
To confirm the effect of the combination on apoptosis, we
examined the expression of the Bcl-2 family proteins. We found
that the combination reduces levels of anti-apoptotic proteins,
p-Bcl-2 and Bcl-xL, and increases pro-apoptotic protein Bim,
compared with either GSI I or radiation alone in both cell lines.
Furthermore, cleaved PARP was induced in single treatment and
combination in both cell lines (Figure 4B).
Combination enhances antitumour activity in vivo
To determine the effect of combining GSI with radiation in vivo,w e
utilised a xenograft model. We previously have shown that GSI
suppressed tumour growth of Notch expressing lung cancer cell
lines, H460 and A549 in vivo (Konishi et al, 2007). The scheduling of
radiation and GSI was outlined in Figure 5A based on our previous
findings (Konishi et al, 2007; Tanaka et al, 2009). The radiation was
given on days 1 and 8 at 8Gy per dose, and GSI XX 200mgkg
 1 was
administered by i.p. injection on days 2–4 and 9–11. We noted a
significant delay in growth of tumours in the combination group
compared with either of the treatments alone (Figure 5B). Some
tumours were resected on day 15 for molecular analysis. Consistent
with our in vitro findings, expression of activated NICD3 was
enhanced in tumours treated with radiation, and this activation was
mitigated by the addition of GSI (Figure 5C). This observation
supports our hypothesis that induction of Notch pathway by
radiation is one mechanism of resistance to radiation and can be
ameliorated by the addition of GSI. Intestinal toxicity has been
major concern in using GSI owing to the loss of intestinal crypts
cells and hyperplasia of intestinal goblet cells (Guilmeau et al,2 0 1 0 ) .
Others reported the observed gut toxicity from GSI was mitigated
with intermittent dosing (Tamman et al, 2009). We stained intestine
of treated mice with periodic acid schiff to examine the intestinal
toxicity of GSI. No increase of intestinal goblet cells was seen among
treated mice compared with controls (data not shown).
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Figure 2 Combination and either GSI or radiation alone regulated the Notch pathway. (A) GSI suppressed Notch intracellular domain (NICD) expression
in a dose-dependent manner. GSI I downregulated NICD1 and NICD3 in HCC2429, whereas NICD3 in H460. (B) Radiation upregulated NICD1, but not
NICD3 in HCC2429, whereas NICD3 in H460 at 24h after radiation (2 or 4Gy). The downstream Notch target gene, HEY1, was also upregulated at 48h
after radiation. (C) Radiation-induced Notch upregulation was ameliorated by the combination. Standardisation was performed with actin measured in the
same blots with anti-actin antibody. Quantifications were shown by the ratios of treated protein expression/untreated protein expression.
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sFurthermore, no body weight loss was encountered (data not
shown), indicating that all treatments, including the combination
therapy was well tolerated.
DISCUSSION
Radiation therapy is the primary treatment for patients with locally
advanced lung cancer. Although it is very effective in local control,
majority of patients will die of their disease, suggesting that further
studies are needed to better understand the mechanisms of
radiation resistance and to develop new strategies to improve
radiation-dependent tumour cytotoxicity.
The phenotypic outcome of Notch signalling is often context-
dependent. In lung cancer, Notch1 was known to suppress tumour
proliferation under normoxia, but in hypoxia, it had a converse
role in tumour promotion (Chen et al, 2007). Moreover, the
specific role of each individual Notch receptor in radiation is not
fully understood, but our present observation that Notch1, but not
Notch3, was enhanced by radiation in HCC2429 also suggests that
the biological function of Notch depends on treatment context,
suggesting that targeting specific Notch receptor may lead to better
outcome by preventing unnecessary toxicity.
In breast cancer, Notch signalling is activated after radiation,
suggesting that activation of this oncogenic pathway is a mecha-
nism of radiation resistance (Phillips et al, 2006). We hypothesised
that Notch activation by radiation has radioprotective role in lung
cancer, this phenomenon can be prevented by the use of Notch
inhibitors after radiation. In our study, we also showed that
radiation-induced Notch activation, which was mitigated by the
administration of GSIs, supporting our hypothesis and providing a
rationale for the sequential treatment schedule.
Enhanced induction of PARP and reduction of pro-survival
proteins, such as p-Bcl-2 and Bcl-xL, by the combination therapy
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Figure 3 Combination treatment induced apoptosis of lung cancer. Cells were treated with GSI I (1mM in HCC2429 and 9mM in H460) at 24h after 8Gy
of radiation. The percentage of apoptotic cells was measured using Annexin V and propidium iodide (PI) with flow cytometry. (A) Representative data of
four independent experiments on HCC2429 and H460. (B) Mean percentage of apoptotic cells. Combination therapy induced significantly higher apoptosis
in HCC2429 and H460 cells (n¼4). *Po0.05.
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Figure 4 Apoptosis was induced through the MAPK pathway and
Bcl-2 family proteins by the combination of GSI and radiation. Cells were
treated with GSI I (1mM in HCC2429 and 9mM in H460) at 24h after
8Gy of radiation. (A) Combination therapy downregulated p-ERK,
but had no effect on p-AKT in either HCC2429 or H460. (B) Combination
therapy downregulated anti-apoptotic proteins, p-Bcl-2 and Bcl-xL, and
upregulated apoptotic proteins, Bim and cleaved PARP, in both HCC2429
and H460.
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ssuggested that the observed antitumour effect is mediated through
induction of apoptosis. Our findings are compatible with the other
reports that GSI or radiation activates the apoptosis pathway,
including Bcl-2 family (Konishi et al, 2007; Han et al, 2009; Zhuang
et al, 2009). Some studies have shown that Notch regulated the
AKT pathway in several cancers (Liu et al, 2006; Meng et al, 2009;
Efferson et al, 2010), but expression of p-AKT was unchanged in
our study, suggesting that the crosstalks between Notch and other
oncogenic pathways are context-dependent.
Cancer stem cells (CSCs) are a small population of cells that are
responsible for tumour maintenance and spreading (Reya et al,
2001; Lobo et al, 2007). CSCs in lung cancer have been isolated and
functions have been described in several reports (Ho et al, 2007;
Eramo et al, 2008). CSCs are further reported to contribute to
resistance of chemotherapy or radiation (Phillips et al, 2006; Ho
et al, 2007; Eramo et al, 2008; Diehn et al, 2009; Rutella et al, 2009).
Notch pathway was activated in several types of CSCs, including
colon cancer, breast cancer and glioma (Dontu et al, 2003; Purow
et al, 2005; Sikandar et al, 2010). For example, radiation appeared
to enhance Notch pathway in both breast cancer (CD24
 /low/
CD44
þ) and glioma (CD133
þ) stem-like cells. The activation of
these cells was accompanied by radioresistance (Phillips et al,
2006; Wang et al, 2010). We did not examine how the combination
therapy affects lung CSCs, as it is unclear that similar markers such
as CD133 or CD44 can be used as markers for lung CSC. However,
our study suggests GSI prevents the induction of CSCs by
radiation, leading to the reduction of tumour growth.
In vivo, we observed a statistically significant delay of tumour
growth in mice with combination therapy. GSI inhibited NICD
both in vitro and in vivo and might get biochemical inhibition at
much lower doses used in vivo than used in vitro. This suggests to
us that the microenvironment contributes to the observable effect.
For example, the Notch ligand DLL4 has a critical role in the
angiogenesis (Ridgway et al, 2006; Scehnet et al, 2007) and GSI has
been shown to inhibit tumour growth through preventing DLL4-
dependent angiogenesis (Li et al, 2011). Furthermore, hypoxic
tumour environment induces radiation resistance (Wilson and
Hay, 2011). Notch 1 was activated under hypoxia in lung cancer
cell lines and GSI-induced apoptosis of these cells (Chen et al,
2007; Eliasz et al, 2010). From these observations and our data, GSI
may not only inhibit tumour cells but also tumour microenviron-
ment, which promotes tumour survival.
In summary, our data provided the evidence that the addition
of GSI enhanced the cytotoxicity of radiation in lung cancer
both in vitro and in vivo. Because of the role of Notch signalling
in tumour hypoxia and CSCs, the radiation-dependent Notch
activation likely represents a mechanism of radioresistence.
Further studies are needed to ascertain our hypothesis. Never-
theless, our study provides compelling evidence that combining
GSI and radiation represents a rational strategy for the treatment
of patients with NSCLC.
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Figure 5 Combination therapy inhibited tumour growth of lung cancer in vivo.( A) Treatment schedule in vivo. H460 and A549 at 1.0 10
6 cells were
inoculated subcutaneously into right posterior legs of nude mice. Treatment was initiated when tumours were palpable. Mice were treated with 200mgkg
 1
GSI XX injected intraperitoneally 3 days per week after 8Gy of radiation once a week. Tumour size was measured every 2 days. Some tumours were
removed on day 15 and the expression of NICD3 was examined by western blot analysis. (B) Combination treatment showed the significant delay of
tumour growth, compared with control or single treatment alone (n¼5). (C) NICD3 expression was upregulated in H460 and A549 tumour treated with
radiation. In contrast, combination therapy reduced NICD3 expression.
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